News

After the Veterans Health Administration tweaked its formulary on an asthma and chronic obstructive pulmonary disease therapy, hospitalizations and emergency department visits increased, according to ...
Associate Health Minister David Seymour is welcoming the moves, saying they're simple changes that cost nothing to anyone.
Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...
GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...
Objectives Care gaps in asthma may be highly prevalent but are poorly characterised. We sought to prospectively measure adherence to key evidence-based adult asthma practices in primary care, and ...
The global house dust mite allergy treatment market size was US$ 1.5 billion in 2021. The global house dust mite allergy treatment market size is forecast to reach US$ 4.6 billion by 2030, growing at ...
Biological drugs have been a game-changer for people with severe asthma, helping them breathe easier and live more ...
The GINA 2025 asthma update includes new guidance on T2 biomarkers, asthma in young children, and climate change, as well as many updated charts and tools.
Credit: Getty Images The GINA 2025 asthma update includes new guidance on T2 biomarkers, asthma in young children, and climate change, as well as many updated charts and tools. The 2025 update also ...
The asthma medication theophylline is a suitable drug for treating the rare neurological disorder ADCY5-related dyskinesia, according to a new study by Martin Luther University Halle-Wittenberg (MLU), ...
Objectives Many patients with asthma spend time and resources consuming complementary and alternative medicines (CAMs). This study explores whether CAM utilisation is associated with asthma control ...
Respiratory nurse lead Carol Stonham outlines what nurses in primary care need to know about changes in the diagnosis and treatment of asthma, following the recent joint guidance from NICE and ...